Methods and compositions using FGF23 fusion polypeptides
AssigneeNovartis AG
InventorsDavid Glass, Shou-Ih Hu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to fusion polypeptides comprising Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof.
Claims18
A functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 53.
A nucleic acid comprising a sequence that encodes a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 53.
A method for activating Egr-1 in an individual, comprising the step of:
- administering to the individual a therapeutically effective dose of a pharmaceutical composition comprising a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide comprises the sequence of SEQ ID NO:
- 53.
A functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide consists of the sequence of SEQ ID NO:
- 53.
A nucleic acid comprising a sequence that encodes a functionally active fusion polypeptide, wherein the sequence of the fusion polypeptide consists of the sequence of SEQ ID NO:
- 53.
Dependencies are inferred from the claim text.